Search

Eli Lilly receives FDA approval for oral weight-loss drug Foundayo

Eli Lilly has obtained US regulatory approval for Foundayo, an oral formulation targeting obesity, intensifying competition with Novo Nordisk's existing pill-based obesity treatments. This approval expands the competitive landscape in the high-growth obesity pharmaceutical market. Market implications include potential pricing pressure and market share redistribution among major pharmaceutical players.